Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains
Aarhus University · Lundbeck Foundation · +66 more institutions
Abstract
Attention-deficit hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder with a major genetic component. Here, we present a genome-wide association study meta-analysis of ADHD comprising 38,691 individuals with ADHD and 186,843 controls. We identified 27 genome-wide significant loci, highlighting 76 potential risk genes enriched among genes expressed particularly in early brain development. Overall, ADHD genetic risk was associated with several brain-specific neuronal subtypes and midbrain dopaminergic neurons. In exome-sequencing data from 17,896 individuals, we identified an increased load of rare protein-truncating variants in ADHD for a set of risk genes enriched with probable causal…
Citation impact
- FWCI
- 148.95
- Percentile
- 100%
- References
- 92
Authors
88- DDDitte DemontisCorresponding
Aarhus University, Lundbeck Foundation
- GBG. Bragi Walters
deCODE Genetics (Iceland), University of Iceland
- GAGeorgios Athanasiadis
Copenhagen University Hospital, Lundbeck Foundation, Institut de Biologia Evolutiva, Capital Region of Denmark, Universitat de Barcelona
- RKRaymond K. Walters
Broad Institute, Harvard University, Massachusetts General Hospital
- KTKaren Therrien
Allen Institute for Brain Science, Icahn School of Medicine at Mount Sinai
Topics & keywords
- Biology
- Genetic architecture
- Genome-wide association study
- Computational biology
- Cognition
- Genetics
- Genome
- Evolutionary biology
Funding
- AUAarhus Universitet
- MDMinisterio de Ciencia, Innovación y UniversidadesAward: IJC2018-035346-I
- ECEuropean CommissionAwards: 965381, Eat2beNICE, H2020, 847879, 728018
- GDGeneralitat de CatalunyaAwards: SLT006/17/287, 2017SGR1461
- NONederlandse Organisatie voor Wetenschappelijk OnderzoekAward: 728018
- LLundbeckfondenAwards: R344-2020-1060, R155-2014-1724, R102-A9118, R102-A9118, R155-2014-1724, R248-2017-2003, and R248-2017-2003
- NNNovo Nordisk
- NFNorges ForskningsrådAward: 288083
- ECEuropean College of NeuropsychopharmacologyAward: 847879
- NNNovo Nordisk FondenAward: NNF20OC0065561
- HLH. Lundbeck A/S
- NINational Institutes of HealthAwards: K08MH122911, APP1172917, U01MH116442, R37MH107649-07S1, T32MH087004, H2020, R01MH125246
- H2Horizon 2020 Framework ProgrammeAwards: Eat2beNICE, 728018, 847879, 965381
- MRMedical Research CouncilAward: MR/L010305/1
- NHNational Health and Medical Research CouncilAwards: APP1172917, APP1103623, APP1158125
- ADAgència de Gestió d'Ajuts Universitaris i de RecercaAward: 2017SGR1461
- IDInstituto de Salud Carlos IIIAwards: PI19/01224, H2020
- EREuropean Regional Development FundAwards: H2020, IJC2018-035346-I
- NINational Institute of Mental HealthAwards: R01MH125246, 1U01MH109514-01, R37MH107649, K08MH122911, U01MH116442, R01MH124851, 1R01MH124851-01, T32MH087004